Quinolones and their therapeutic use

A compound of formula (I), wherein R represents a bicyclic structure in which a cycloalkyl or heterocyclo ring is bound to NH and is fused to a second ring selected from aryl or heteroaryl, and in which either or each ring is optionally substituted by one or more substituents chosen from halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C1-6 alkyl amides thereof), C1-6 alkyl, NR R and SO2NR R ; R , R and R are the same or different and represent H, halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C1-6 alkyl amides thereof), NR R , SO2NR R or C1-6 alkyl in which alkyl is optionally substituted with halo, C1-6 alkoxy, hydroxy, CN, CO2H (or C1-6 alkyl esters or C1-6 alkyl amides thereof), NR R or SO2NR R , or any adjacent two substituents R -R are joined to form an optionally substituted carbocyclic aromatic, heteroaromatic, saturated carbocyclic or heterocyclic ring; R and R are the same or different and represent H, C1-6 alkyl, cycloalkyl, C1-6 alkylcarbonyl, arylcarbonyl, C1-6 alkoxycarbonyl, arylsulphonyl or C1-6 alkylsulphonyl, or NR R is a 5 or 6-membered ring such as pyrrolidine, piperidine, morpholine or piperazine; X represents a linking group selected from -(CR R )2-3-, -Y-(CR R )2-, -(CR R )2-Y-, -CR R -Y-CR R - and -Y-CR R -Z-, Y and Z being independently NR , O or S(O)0-2, provided that Y and Z are not both S(O)0-2; Q represents O or S; and each R , each R and R are the same or different and are H or C1-6 alkyl; or a pharmaceutically-acceptable salt, solvate or hydrate thereof.